[Barbexaclone in the treatment of the epilepsies (author's transl)].
Chronic administration of barbiturates in the treatment of the epilepsies causes sedation. The association of C.N.S. stimulant agents appears to offer a possible advantage. 19 epileptic outpatients were followed up during an "open" trial of barbexaclone (L-1-cyclohexyl-2-methylaminopropan-phenyl-ethyl-barbiturate) over a period of about one year. The drug was effective in primary and secondarily generalized epilepsies, and to a lesser extent in partial complex seizures. The tolerability was good and a reduction of the side-effects due to previous treatment with phenobarbitone has been noticed. The mean dosage of barbexaclone was lower in patients who improved than in those who remained unchanged.
D000293:Adolescent; D000328:Adult; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000031:analogs & derivatives* / Q000627:therapeutic use
C011019:barbexaclone; D010634:Phenobarbital
Il barbexaclone nel trattamento delle epilessie.